Tehran, Iran—The Iranian Journal of Pharmaceutical Research published new data suggesting that a branded curcumin ingredient supports heart health.
For two months, 33 coronary artery disease patients took a placebo or 2,000 mg of curcumin (as 500 mg capsules, four times daily, Curcumin C3 Complex from Sabinsa). Researchers took bloodwork to track their lipid, glucose and C-reactive protein (CRP) levels. At the end of the study, those taking curcumin had lower triglyceride and LDL-/VLDL-cholesterol levels, but did not have much change in their HDL cholesterol, glucose or CRP levels.
The researchers concluded, “Further and larger human studies need to be done in order to establish a detailed assessment of metabolic effects and or anti-inflammatory actions of curcumin.”
Published in WholeFoods Magazine Online, 5/19/15